The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia

• Main Authors: Rauzan M., Chuah C.T.H., Ko T.K., Tiong Ong S.
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: Public Library of Science 2020
• Subjects: BCR ABL protein; BIM protein; imatinib; pracinostat; protein tyrosine kinase inhibitor; antineoplastic agent; benzimidazole derivative; enzyme inhibitor; histone deacetylase inhibitor; SB939 compound; apoptosis; Article; BIM gene; cancer resistance; cell viability; chronic myeloid leukemia; controlled study; DNA polymorphism; drug efficacy; drug mechanism; drug sensitivity; gene; gene deletion; human; human cell; leukemia cell; RNA splicing; antagonists and inhibitors; drug effects; genetics; K-562 cell line; pathology; Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Benzimidazoles; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Deletion; Histone Deacetylase Inhibitors; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; RNA Splicing
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/166015
• Institution: National University of Singapore

10.1371/journal.pone.0174107